Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. - Wikidata - wikimedia - TriplyDB

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

http://www.wikidata.org/entity/Q34806348

about

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer Selected cytokines in patients with pancreatic cancer: a preliminary report.Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.Significance of Interleukin-6 in Papillary Thyroid Carcinoma.Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.Biomarkers for pancreatic cancer: recent achievements in proteomics and genomics through classical and multivariate statistical methods.Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies.Are SMAD7 rs4939827 and CHI3L1 rs4950928 polymorphisms associated with colorectal cancer in Egyptian patients?Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population.Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer

P2860

Q26741263-D7E7ABA1-7257-4FF6-8868-3C696F56BF19 Q33573132-1E264BC6-ABBA-4745-856D-32E1E495DC94 Q33645140-EA90371F-4DE6-4A4D-8052-059E6B4FCA0E Q36015280-0797B2AE-6EA5-4C9A-8009-700A82EB1829 Q36731164-DE7C3221-8791-4C74-AC57-B8F9A48E3485 Q36902015-AA74254A-5431-4185-9327-CFD4C656CDB6 Q38259536-77B1AD40-9312-44EA-99C0-AC94D8E9275C Q38393888-67A92FA8-9D71-4972-8A67-09A098C299ED Q38852978-34367783-88A4-4524-BD89-A86F69AB5E52 Q39414719-0C99017C-35BE-483B-9A7B-A6BA22BF89BC Q41653273-CD1E7C44-951C-4A79-929D-7F7FC9E5EAB2 Q57115352-4B4C5B0E-D6F5-431F-ACA2-7368576537CB

P2860

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

http://www.wikidata.org/entity/Q34806348

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@ast

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@en

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@nl

type

label

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@ast

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@en

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@nl

prefLabel

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@ast

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@en

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@nl

P1433

Q34806348-9170279B-1157-40C5-AEF8-D791C9AC04DC

P1476

Q34806348-72F077C1-F6E7-4E98-BFEA-A081296AB01C

P2093

Q34806348-18DA4E4A-D353-48C6-95F7-D50C3A79A906

Q34806348-1C8DF841-D6EC-4E74-837F-3C387194AC70

Q34806348-2C3DB14E-D7BE-4433-9F55-3A4C5F965161

Q34806348-4E2CE8F4-97C4-486B-B589-120B42DBC93E

Q34806348-5BA849A7-EFBF-4236-9E23-4955FD368785

Q34806348-75F77AAA-5607-48F7-8F10-0E0CAC1A1D3C

Q34806348-880020E5-C80E-4E40-88CC-7ACA4A02DD70

Q34806348-8A47FEB9-C848-45B8-8A8B-BF4FF40E591E

Q34806348-9BB00B82-4EC4-4644-8F6C-53D50CAA8443

Q34806348-9D9A869A-F327-4F8C-9D14-FC3E6F6713E3

P2860

Q34806348-00C59456-8789-47F2-8C86-E5C92460C944

Q34806348-1471F9D2-1F10-4E9F-B963-3ED65E9CA346

Q34806348-175B9F68-812B-4305-BCC0-3EB2E930885C

Q34806348-220BED4A-66FB-4AF2-9E9F-937E58CD843D

Q34806348-281223B8-90E6-4C57-8BF5-A36622934A89

Q34806348-2D32AC17-753B-4E3E-B238-C500E334C4A5

Q34806348-362AB11F-99F6-41FF-8D00-4AC3D70B8238

Q34806348-36E900EB-7B7C-4DAB-A147-A9AE85635369

Q34806348-395CB82B-E3E1-423A-A1D2-067B3F087187

Q34806348-396258BE-4216-4368-81A9-0A3569BD6309

P304

Q34806348-23BB258E-FDAE-4664-8DAD-F592285DFD07

P31

Q34806348-B41855F4-1E2D-491C-BEFA-D43B47A4DA74

P356

Q34806348-EC071ED1-9BFF-4EA7-82DC-65EB637A7860

P407

Q34806348-418F55EE-5535-4CE9-B19E-A7AE05E2E2E5

P433

Q34806348-76E34DC9-7A76-4F89-838D-BAED8B630C9C

P478

Q34806348-A04A9949-6EF4-4666-9FBB-17048B884920

P50

Q34806348-82BA4223-4EB4-4905-9D9F-71366485CE7B

Q34806348-E1E58E3A-8B3B-455E-870C-CF0F14B389B8

P577

Q34806348-A8C6F7DD-866B-44F4-A82C-2A834A4AE2CA

P5875

Q34806348-FD2A61BE-AD45-44AD-A9C4-A7A200D9EA29

P698

Q34806348-7773A983-15DA-4EB9-82F7-7BFC0DC81D46

P932

Q34806348-CDBC0598-03B9-40DB-AD50-940C24F95749

P356

JOURNAL.PONE.0067059

P1433

P1476

Diagnostic and Prognostic Impa ...... tients with Pancreatic Cancer.

@en

P2093

Benny V Jensen

http://www.w3.org/2001/XMLSchema#string

Dan Calatayud

http://www.w3.org/2001/XMLSchema#string

Ib J Christensen

http://www.w3.org/2001/XMLSchema#string

Jens Werner

http://www.w3.org/2001/XMLSchema#string

Jon K Bjerregaard

http://www.w3.org/2001/XMLSchema#string

Julia S Johansen

http://www.w3.org/2001/XMLSchema#string

Kaspar R Nielsen

http://www.w3.org/2001/XMLSchema#string

Mette K Yilmaz

http://www.w3.org/2001/XMLSchema#string

Morten Wøjdemann

http://www.w3.org/2001/XMLSchema#string

Nicolai A Schultz

http://www.w3.org/2001/XMLSchema#string

P2860

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Hallmarks of Cancer: The Next Generation

Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma

IL-6, but not TNF-α, increases plasma YKL-40 in human subjects

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers

Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells

Cancer statistics, 2012

Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation

Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells

P304

e67059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0067059

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Stig Egil Bojesen

P577

2013-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248385747

http://www.w3.org/2001/XMLSchema#string

P698

23840582

http://www.w3.org/2001/XMLSchema#string

P932

3694124

http://www.w3.org/2001/XMLSchema#string